---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-131957"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2024-12-27T23:59:59+00:00"
generated_at: "2026-05-28T23:04:12.035584+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics reports FY2024 net loss of $75.4M; LYTENAVA launch plans for H1 2025

## Summary
- Net loss of $75.4M ($4.06 per share) vs $59.0M ($4.72 per share) in prior fiscal year.
- Cash and cash equivalents of $14.9M as of September 30, 2024.
- LYTENAVA (bevacizumab gamma) approved in EU and UK for wet AMD; NICE recommends in UK.
- NORSE EIGHT month 3 efficacy data expected January 2025; BLA resubmission targeted Q1 2025.
- First commercial launches in UK and Germany planned H1 2025; potential US FDA approval H2 2025.

## SEC filing metadata
- accession: 0001104659-24-131957
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2024-12-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465924131957/0001104659-24-131957-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465924131957/tm2431904d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-131957
- JSON: https://secwatch.observer/filing/0001104659-24-131957.json
- Plain text: https://secwatch.observer/filing/0001104659-24-131957.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.